CHU de Toulouse-Hopital Rangueil

Toulouse 31400

2 studies enrolling now · 16 studies all time

What they study most

Acute Myocardial Infarction, Amyloid Cardiomyopathy, Amyloidosis, Cardiomyopathies, Congestive Heart Failure, Crohn Disease, Crohn's Disease, Delayed Graft Function, Heart Diseases, Hyperlipidemia, Polyneuropathies, Pouchitis

Studies at this site

• Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant — Recruiting now
• MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) — Recruiting now
• An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis — Running, not enrolling
• ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function — Running, not enrolling
• Transthyretin Amyloidosis Outcome Survey (THAOS) — Completed
• Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease — Stopped early
• Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease — Completed
• Study of Cilofexor in Adults With Primary Sclerosing Cholangitis — Stopped early
• IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction — Completed
• A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis — Completed
• Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis — Completed
• Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease — Stopped early
• A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease — Stopped early
• Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events — Completed
• A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease — Withdrawn before enrolling